{
  "meta": {
    "generated_at": "2026-01-09T00:53:42.199Z",
    "total_signals": 33,
    "filter": "Strong/Confirmed Signals Only"
  },
  "signals": [
    {
      "ticker": "NIVABUPA.NS",
      "signal": "BUY",
      "price": 79.5199966430664,
      "market": "IN",
      "technical_context": "Supertrend Flip (Orig SL: 73.15, Orig TP: 98.64)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "INOXINDIA.NS",
      "signal": "BUY",
      "price": 1162.5,
      "market": "IN",
      "technical_context": "CE+QQE (Orig SL: 1089.75, Orig TP: 1380.76)",
      "analysis": {
        "ticker": "INOXINDIA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 90,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal is strongly supported by fundamental data. INOX India reported robust Q2 FY26 earnings with ~23% YoY profit growth and ~17% revenue growth, driven by strong demand in the Industrial Gas and LNG segments. The company holds a record order book (over ₹1,400 Cr), including prestigious contracts from ITER and expanding global exports. Technically, the stock has recently crossed key moving averages (200-DMA) and is building momentum to challenge its 52-week high of ₹1,289. Analyst consensus is a 'Strong Buy' with targets ranging from ₹1,400 to ₹1,600, validating the signal's target of ₹1,380.",
        "fundamental_summary": "INOX India is a debt-free leader in cryogenic storage, benefitting from the global clean energy transition. Q2 FY26 results highlighted improving margins (EBITDA margins stable/improving) and record order inflows from clean energy (LNG/Hydrogen) and scientific sectors. The company is actively expanding its footprint in semiconductor material storage and LNG transport.",
        "catalysts": [
          "Record order book backlog providing revenue visibility for FY26-27.",
          "Expansion into Green Hydrogen and semiconductor-grade gas storage solutions.",
          "Strong Q2 FY26 earnings report showing 23% YoY PAT growth.",
          "Recent technical breakout above the 200-day moving average."
        ],
        "tradeSetup": {
          "entryZone": "1160 - 1170 INR",
          "stopLoss": "1085 INR",
          "targetPrice": "1380 - 1450 INR",
          "riskRewardRatio": "1:2.8"
        },
        "sources": [
          {
            "title": "scanx.trade",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHXcNb00RaxuSwYH6VITxoBM2fSqI8H9wPC61WFANRUrEyrwiKdR7oa865BOR_89z5g-vxHYX4tyF9CTZNDgqhdew7i0aObwLbGNRLj3_4z3GDvkS2GBZC_kPI8MbQk71qAm0wQEqHv1hSXAWzsog0lYE26aURyt-XrKlsv-jsJrIa5BKPzuWDoZuBeztGfZyBMz9FyKpUDph2tCRqnlC03_GogzEZkjA_yH-LmxHVAeU7At38VkeL4ZmmFkI-6Mt_aF8989Dy0gMzg06XC"
          }
        ]
      }
    },
    {
      "ticker": "ONESOURCE.NS",
      "signal": "BUY",
      "price": 1785.9000244140625,
      "market": "IN",
      "technical_context": "EMA 50/200 Cross (Orig SL: 1670.16, Orig TP: 2133.11)",
      "analysis": {
        "ticker": "ONESOURCE.NS",
        "sentiment": "Bullish",
        "confidenceScore": 90,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (EMA 50/200 Cross) is strongly supported by the fundamental backdrop. OneSource Specialty Pharma (recently demerged from Strides Pharma) is a primary beneficiary of the 'US Biosecure Act', which mandates US pharmaceutical companies to diversify supply chains away from China, directly favoring Indian CDMOs. The company has recently raised its FY28 revenue guidance to $500M, driven by surging demand for GLP-1 (weight loss) drug manufacturing. Analyst consensus (ICICI Securities, JM Financial) is a 'Strong Buy' with targets ranging from ₹2,113 to ₹2,531, validating the upside potential from the current price of ₹1,785.",
        "fundamental_summary": "OneSource Specialty Pharma is a pure-play Contract Development and Manufacturing Organization (CDMO) specializing in high-growth niches like Biologics, Complex Injectables, and Soft Gelatin Capsules. Following its demerger from Strides Pharma (listed Jan 2025), it has become a key player in the 'China+1' strategy. Financials are robust, with Q2 FY26 revenue growing ~14% QoQ and EBITDA margins expanding due to a favorable mix shift towards high-margin biologics.",
        "catalysts": [
          "US Biosecure Act implementation (Strategic tailwind impacting Chinese competitors)",
          "Ramp-up of GLP-1 (Weight Loss Drug) manufacturing capacity",
          "Analyst upgrades with targets ~₹2,500 (ICICI Securities, JM Financial)",
          "Strong Q2 FY26 earnings growth and FY28 guidance hike"
        ],
        "tradeSetup": {
          "entryZone": "1780 - 1800 (CMP: 1785.90)",
          "stopLoss": "1670.00 (Below recent swing low/200 DMA support)",
          "targetPrice": "2133.00 (Technical Target) -> 2530.00 (Analyst Target)",
          "riskRewardRatio": "1:3"
        },
        "sources": []
      }
    },
    {
      "ticker": "DIVISLAB.NS",
      "signal": "BUY",
      "price": 6600.5,
      "market": "IN",
      "technical_context": "CE+QQE (Orig SL: 6340.77, Orig TP: 7379.69)",
      "analysis": {
        "ticker": "DIVISLAB.NS",
        "sentiment": "Bullish",
        "confidenceScore": 85,
        "validation": "Confirm",
        "reasoning": "Divi's Laboratories validates the BUY signal with strong fundamental momentum entering 2026. Q2 FY26 earnings (reported Nov 2025) showed robust growth with Revenue up 17% YoY and PAT surging 35% YoY to ₹689 Cr, driven by the Custom Synthesis (CDMO) segment and GLP-1 opportunity. The Kakinada facility, now operational, provides clear revenue visibility for FY27. Technically, the stock is holding above key support at 6300-6400, and the CE+QQE signal aligns with the primary uptrend. Analyst upgrades (High targets ~7400-7800) reinforce the potential for a breakout above the 52-week high of ~7078.",
        "fundamental_summary": "Divi's Lab is in a high-growth phase (FY26) with CDMO segment recovery and new capacity at Kakinada coming online. Q2 FY26 consolidated revenue stood at ₹2,860 Cr (+17% YoY) with EBITDA margins expanding to ~32%. The company is a key beneficiary of the 'Biosecure Act' and supply chain diversification (China+1), particularly in peptide and contrast media synthesis. Valuation remains premium (~70x PE) but is justified by accelerating 30%+ earnings growth.",
        "catalysts": [
          "Ramp-up of production at the new Kakinada facility (Unit-III) contributing to Q3/Q4 FY26 revenue.",
          "Upcoming Q3 FY26 earnings (Expected Feb 2026) likely to show sustained margin expansion.",
          "Continued traction in Custom Synthesis for GLP-1 agonists and contrast media APIs."
        ],
        "tradeSetup": {
          "entryZone": "6600 - 6650",
          "stopLoss": "6340",
          "targetPrice": "7380",
          "riskRewardRatio": "1:3"
        },
        "sources": [
          {
            "title": "nseindia.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEcmGyAQxTYFI7Kd2WgpmFC8-Q6HH1T7HjoWKu9_7qJ3MxRiPjoKAPaBcLtwQsvXwUu_CLHaDHoml7vTNbfg0_RwXelEtPQZF77k3_J3fdi70_a6y2QRq1cW1rIUGuGx9IDDRlPO7wk5Rme9J58RGRyTRGaLNA_t2yMyPrPcoK5-DGDZPQnlHsSaQ=="
          }
        ]
      }
    },
    {
      "ticker": "HYUNDAI.NS",
      "signal": "BUY",
      "price": 2350.5,
      "market": "IN",
      "technical_context": "CE+QQE (Orig SL: 2244.80, Orig TP: 2667.59)",
      "analysis": {
        "ticker": "HYUNDAI.NS",
        "sentiment": "Bullish",
        "confidenceScore": 85,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal is strongly supported by fundamental and macroeconomic factors as of January 2026. While December 2025 sales showed a marginal YoY decline (-2.4%), the broader context is bullish due to the recent 'GST 2.0' rate rationalization which has improved affordability and revived consumer sentiment in the auto sector. Analysts maintain a 'Buy' consensus with price targets averaging around ₹2,660-₹2,800, implying decent upside from current levels (~₹2,350). The appointment of Tarun Garg as MD & CEO (effective Jan 1, 2026) and the upcoming launch of the Creta Electric are key positive catalysts. Technically, a recent 50-day moving average crossover confirms bullish momentum.",
        "fundamental_summary": "Hyundai Motor India reported strong resilience in CY2025 despite industry headwinds, with annual domestic sales exceeding 6 lakh units. Q2 FY26 financials (ending Sept 2025) showed revenue growth and improved EBITDA margins (13.9%). The company is benefitting from the recent GST 2.0 reforms which have boosted the mass-market and SUV segments. Upcoming Q3 FY26 earnings (expected Feb 2, 2026) are anticipated to reflect this improved sentiment.",
        "catalysts": [
          "Impact of GST 2.0 rate rationalization boosting auto affordability.",
          "Upcoming launch of Creta Electric vehicle.",
          "Strong Q4 FY26 demand outlook driven by the marriage season (Jan-Mar).",
          "Leadership transition with Tarun Garg taking over as MD & CEO."
        ],
        "tradeSetup": {
          "entryZone": "2350 - 2360",
          "stopLoss": "2240",
          "targetPrice": "2660 - 2700",
          "riskRewardRatio": "1:3"
        },
        "sources": [
          {
            "title": "trendlyne.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHXvaOBEoUmu2EOy0G1EYc-XDwXDr3SObUged29FlPJdpa3icBVnKnlOh8fhoWkxqAozYi7knoyxHpBnWMU7pzEtNwIrtTNnGre9jlxmU81BcoWfrns-rsta-X2hiwYY0qXgmQdrSjM64WQowLvueeGu-1ebrvhQHw-VoHNBlbvJoYjIyvzS9X8ie1Rjv_V1io="
          },
          {
            "title": "quartr.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHOt43Qu4hlaJUTfdyVRpr8GGw3C9RwAtTUKZDq4eUFI0-3yOGZkQ4bte7ypgGs8TqvbnIW3yqIz640X-Ua1g2hcYIHqhYNeZBrnXYXW3dMdxHj95g-vsB_JfwDB5aW6EBVMKsmrGCtzakXteLg2yUJjqq2v2hnfuE="
          },
          {
            "title": "investing.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFn-hZXQHsgB9LnLYq2dAdBj8SSYQpTtmtmrtF6uxYjktCH6fkyreJGA97huiWqWKYnkPztEnXSzJ12VOt4A4spoHK0b1fiEwSsbaysinrspKiAWs-MeHYvMgQFUUYzL6mQiWGYalioWN7iqILoWmVr0esPC_8kQo4="
          }
        ]
      }
    },
    {
      "ticker": "KOTAKBANK.NS",
      "signal": "SELL",
      "price": 2133,
      "market": "IN",
      "technical_context": "CE+QQE (Orig SL: 2215.53, Orig TP: 1885.42)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "THELEELA.NS",
      "signal": "BUY",
      "price": 418.54998779296875,
      "market": "IN",
      "technical_context": "EMA 50/200 Cross (Orig SL: 392.28, Orig TP: 497.36)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "GODIGIT.NS",
      "signal": "SELL",
      "price": 335.8999938964844,
      "market": "IN",
      "technical_context": "Supertrend Flip (Orig SL: 359.54, Orig TP: 264.97)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "ULTRACEMCO.NS",
      "signal": "BUY",
      "price": 12064,
      "market": "IN",
      "technical_context": "EMA 50/200 Cross (Orig SL: 11760.56, Orig TP: 12974.32)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "DMART.NS",
      "signal": "BUY",
      "price": 3789.800048828125,
      "market": "IN",
      "technical_context": "CE+QQE (Orig SL: 3634.99, Orig TP: 4254.23)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "TRIVENI.NS",
      "signal": "SELL",
      "price": 365.3999938964844,
      "market": "IN",
      "technical_context": "Supertrend Flip (Orig SL: 400.73, Orig TP: 259.42)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "INDHOTEL.NS",
      "signal": "SELL",
      "price": 704.3499755859375,
      "market": "IN",
      "technical_context": "CE+QQE (Orig SL: 745.22, Orig TP: 581.74) | Supertrend Flip (Orig SL: 753.42, Orig TP: 557.13)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "MAHSEAMLES.NS",
      "signal": "SELL",
      "price": 541.3499755859375,
      "market": "IN",
      "technical_context": "Supertrend Flip (Orig SL: 585.22, Orig TP: 409.73)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "IRCTC.NS",
      "signal": "SELL",
      "price": 656.4500122070312,
      "market": "IN",
      "technical_context": "Supertrend Flip (Orig SL: 704.54, Orig TP: 512.17)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "ATHERENERG.NS",
      "signal": "SELL",
      "price": 672.7000122070312,
      "market": "IN",
      "technical_context": "CE+QQE (Orig SL: 755.11, Orig TP: 425.48) | EMA 50/200 Cross (Orig SL: 611.07, Orig TP: 857.59)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "AMBUJACEM.NS",
      "signal": "SELL",
      "price": 546.7000122070312,
      "market": "IN",
      "technical_context": "Supertrend Flip (Orig SL: 580.59, Orig TP: 445.03)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "DRREDDY.NS",
      "signal": "SELL",
      "price": 1206.9000244140625,
      "market": "IN",
      "technical_context": "Supertrend Flip (Orig SL: 1285.66, Orig TP: 970.62)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "CENTURYPLY.NS",
      "signal": "SELL",
      "price": 782,
      "market": "IN",
      "technical_context": "CE+QQE (Orig SL: 847.03, Orig TP: 586.92)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "TECHM.NS",
      "signal": "SELL",
      "price": 1577.9000244140625,
      "market": "IN",
      "technical_context": "CE+QQE (Orig SL: 1661.36, Orig TP: 1327.52)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "JSWCEMENT.NS",
      "signal": "BUY",
      "price": 119.97000122070312,
      "market": "IN",
      "technical_context": "EMA 50/200 Cross (Orig SL: 113.87, Orig TP: 138.26)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "WIPRO.NS",
      "signal": "SELL",
      "price": 262.20001220703125,
      "market": "IN",
      "technical_context": "CE+QQE (Orig SL: 276.29, Orig TP: 219.92)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "GRAVITA.NS",
      "signal": "SELL",
      "price": 1726.9000244140625,
      "market": "IN",
      "technical_context": "CE+QQE (Orig SL: 1869.10, Orig TP: 1300.30) | Supertrend Flip (Orig SL: 1899.97, Orig TP: 1207.70)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "SUMICHEM.NS",
      "signal": "SELL",
      "price": 445.45001220703125,
      "market": "IN",
      "technical_context": "Supertrend Flip (Orig SL: 491.62, Orig TP: 306.94)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "NBCC.NS",
      "signal": "SELL",
      "price": 112.08999633789062,
      "market": "IN",
      "technical_context": "Supertrend Flip (Orig SL: 124.48, Orig TP: 74.91)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "BPCL.NS",
      "signal": "SELL",
      "price": 354.54998779296875,
      "market": "IN",
      "technical_context": "Supertrend Flip (Orig SL: 389.21, Orig TP: 250.56)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "WOCKPHARMA.NS",
      "signal": "BUY",
      "price": 1458.4000244140625,
      "market": "IN",
      "technical_context": "EMA 50/200 Cross (Orig SL: 1346.92, Orig TP: 1792.83)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "RADICO.NS",
      "signal": "SELL",
      "price": 3079.39990234375,
      "market": "IN",
      "technical_context": "CE+QQE (Orig SL: 3362.34, Orig TP: 2230.59)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "KEC.NS",
      "signal": "SELL",
      "price": 684.7999877929688,
      "market": "IN",
      "technical_context": "Supertrend Flip (Orig SL: 758.70, Orig TP: 463.11)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "HINDPETRO.NS",
      "signal": "SELL",
      "price": 452.20001220703125,
      "market": "IN",
      "technical_context": "Supertrend Flip (Orig SL: 506.66, Orig TP: 288.82)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "JINDALSTEL.NS",
      "signal": "SELL",
      "price": 1013.5999755859375,
      "market": "IN",
      "technical_context": "Supertrend Flip (Orig SL: 1127.03, Orig TP: 673.31)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "HINDZINC.NS",
      "signal": "SELL",
      "price": 590.75,
      "market": "IN",
      "technical_context": "Supertrend Flip (Orig SL: 672.46, Orig TP: 345.62)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "SIGNATURE.NS",
      "signal": "SELL",
      "price": 991.5999755859375,
      "market": "IN",
      "technical_context": "CE+QQE (Orig SL: 1050.26, Orig TP: 815.63) | Supertrend Flip (Orig SL: 1151.95, Orig TP: 510.55)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    },
    {
      "ticker": "BHEL.NS",
      "signal": "SELL",
      "price": 271.75,
      "market": "IN",
      "technical_context": "Supertrend Flip (Orig SL: 320.04, Orig TP: 126.87)",
      "analysis": {
        "ticker": "NIVABUPA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative in early 2026. While Q2 FY26 earnings (Nov 2025) showed some weakness/losses causing a price dip, the stock found strong support near its IPO price of ₹74. A major sector catalyst—the removal of GST on health insurance (reported Dec 2025)—is driving renewed investor interest. Multiple analysts maintain a 'Buy' rating with consensus targets between ₹86 and ₹91. The technical breakout is further supported by a recent MACD bullish crossover (Jan 7, 2026), indicating momentum is shifting back to the upside.",
        "fundamental_summary": "Niva Bupa is a recently listed Standalone Health Insurer (SAHI). Despite reporting a net loss of ~₹35 Cr in Q2 FY26 (Sep 2025) due to high operational costs, the company maintains strong top-line growth (Premium growth ~17-24% YoY). The removal of GST on health premiums serves as a significant macro tailwind, expected to boost adoption and margins. Valuation is stabilizing as it trades near its IPO issuance levels.",
        "catalysts": [
          "Removal of GST on health insurance premiums (Dec 2025 news) boosting sector sentiment.",
          "Analyst consensus targets of ₹91 indicating ~15% upside.",
          "Technical recovery from IPO base support (₹74).",
          "Sector growth projection of 22% CAGR for SAHIs in 2026."
        ],
        "tradeSetup": {
          "entryZone": "₹79.00 - ₹80.00",
          "stopLoss": "₹73.00",
          "targetPrice": "₹91.00",
          "riskRewardRatio": "1:2"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0o3qFPXRS-_sSKwNeSCqEfGXB5HgWPDqwqgjVMcpDaTFslXxThEi4-QauFx6bicjB9dR0JXCOZcwbfwmfNKtOFNmBu1WBTbCU80Qr7CBr1_TX5VdC_BC8i_FEKAyIKfCKlhmRE64V8gQcPlI3qXJqa4Virzhnr1k4sP35MvOJA7v-yEf_wWV202ajPRtKnW8A2RI_BjEvF3NPBkphsYOBmiDtFTPgVlPKcMI5O_fUwj1UfIm9lx3exoq4SfBxJOAlWeqxaEuJYbjLRqGN"
          }
        ]
      }
    }
  ]
}